Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click on 'Find out more' to see our Cookie statement.

OxSyBio, an Oxford University biotech spinout company developing 3D printer technology capable of printing biological materials with a diverse range of therapeutic purposes, has secured £10m in Series A financing from Woodford Investment Management alongside new and existing backers.

© Oxford University/G Villar

OxSyBio has a unique 3D printing platform which enables it to assemble the building blocks of life. The synthetic biology company's ultimate ambition is to fabricate therapeutic tissues for patients using living cells or non-living 'artificial' cells, or hybrid materials.

These tissues have the potential to revolutionise the growing field of regenerative medicine, allowing for the literal printing of new tissues that can be used to repair or replace parts of the body damaged through disease or injury.

OxSyBio, which is underpinned by research conducted in the lab of Professor Hagan Bayley, the founding academic behind Oxford Nanopore Technologies, was spun out from Oxford University’s Department of Chemistry by the institution’s innovation arm Oxford University Innovation in 2014.

The Series A – the name typically given to a company's first significant round of venture capital financing – was led by Woodford Investment Management, with participation from IP Group plc and Parkwalk Advisors Ltd. The round, part of which is subject to the achievement of milestones, builds on the previous £1m seed funding, bringing OxSyBio's total fundraising to date to £11m. The latest investment will enable the company to further develop its artificial cell platform and 3D bioprinting technology to develop disruptive products that harness the power of biology for impact in medicine.

Dr Hadrian Green, CEO of OxSyBio, said: 'Biological functions are difficult to create using electrical or mechanical devices, therefore harnessing the power of biological materials in non-living devices will be highly disruptive. This investment is testament to the power of the original ideas and the hard work of our Chief Technology Officer Sam Olof, the OxSyBio team and the founding lab to turn research into reality. OxSyBio wishes to pay tribute to Oxford University and the unique culture of patient capital, pioneered by Neil Woodford and IP Group, which is instrumental to delivering long-term transformational technologies.'

Moray Wright, Chief Executive Officer at Parkwalk Advisors, said: 'The 3D printing of tissues from living cells in high-throughput formats is already proving interesting to academic and pharmaceutical research teams, with massive potential impact right across the board. The concept of artificial cells has had a long history, but with OxSyBio's platform technology, the concept is becoming a reality.'

Professor Hagan Bayley added: 'This deal provides the long-term capital required to deliver our ambition of building affordable tissues for patients. The company has already made important strides in translating this technology into a real world product, and we look forward to continuing our close research collaboration.'

Story courtesy of the University of Oxford News Office

Similar stories

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Chemistry Funding Medical science Zoology

Ineos, one of the world’s largest manufacturing companies, and the University of Oxford are launching a new world-leading institute to combat the growing global issue of antimicrobial resistance (AMR), which currently causes an estimated 1.5 million excess deaths each year.

Eight Oxford researchers, including five from MPLS, awarded major European Research Council funding

Chemistry Engineering Funding Plant sciences Zoology

European Research Council grants worth more than €16.3 million have been awarded to University of Oxford researchers for a range of cutting-edge projects.

$10 million gift for new Nanoscience Institute in Oxford

Biomedical engineering Chemistry Engineering Funding Materials science Medical science Physics

A new institute for nanoscience research is to open in Oxford thanks to a $10 million gift from The Kavli Foundation.

Low-cost ventilator wins at E&T Innovation Awards

Award COVID-19 Engineering Innovation and Enterprise

OxVent is a rapidly deployable and scalable low-cost mechanical ventilator specially designed for COVID-19, which has now been recognised as one of the best innovations of the year by the Institute of Engineering and Technology.

Rapid COVID-19 test, Oxsed RaViD Direct, now in use at Heathrow and trials at Hong Kong International Airport

COVID-19 Engineering Spin out

The spinout company, Oxsed, was last month acquired by DNAFit Life Sciences, a wholly owned entity of Hong Kong-based genetics and diagnostic health testing company Prenetics. Deploying the test to further global airports is now under discussion.

Institute of Physics awards for MPLS researchers

Award Chemistry Physics

Three MPLS academics and researchers have been awarded 2020 IOP Medals for their contributions to Physics - two in the Department of Physics and one in the Department of Chemistry.

Similar stories

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Chemistry Funding Medical science Zoology

Ineos, one of the world’s largest manufacturing companies, and the University of Oxford are launching a new world-leading institute to combat the growing global issue of antimicrobial resistance (AMR), which currently causes an estimated 1.5 million excess deaths each year.

Eight Oxford researchers, including five from MPLS, awarded major European Research Council funding

Chemistry Engineering Funding Plant sciences Zoology

European Research Council grants worth more than €16.3 million have been awarded to University of Oxford researchers for a range of cutting-edge projects.

$10 million gift for new Nanoscience Institute in Oxford

Biomedical engineering Chemistry Engineering Funding Materials science Medical science Physics

A new institute for nanoscience research is to open in Oxford thanks to a $10 million gift from The Kavli Foundation.

Low-cost ventilator wins at E&T Innovation Awards

Award COVID-19 Engineering Innovation and Enterprise

OxVent is a rapidly deployable and scalable low-cost mechanical ventilator specially designed for COVID-19, which has now been recognised as one of the best innovations of the year by the Institute of Engineering and Technology.

Rapid COVID-19 test, Oxsed RaViD Direct, now in use at Heathrow and trials at Hong Kong International Airport

COVID-19 Engineering Spin out

The spinout company, Oxsed, was last month acquired by DNAFit Life Sciences, a wholly owned entity of Hong Kong-based genetics and diagnostic health testing company Prenetics. Deploying the test to further global airports is now under discussion.

Institute of Physics awards for MPLS researchers

Award Chemistry Physics

Three MPLS academics and researchers have been awarded 2020 IOP Medals for their contributions to Physics - two in the Department of Physics and one in the Department of Chemistry.